mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Portfolio

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. Four products are in the registration phase of clinical studies.

Hepatera is a Russian biotechnology company founded in 2011 with the goal to develop and launch into the Russian market innovative products for treatment of liver diseases. Since December 2011 Hepateraha become a resident of Skolkovo Biomed Cluster.

First product (Myrcludex B) is aimed at the treatment of chronic hepatitis B and D.

http://www.hepatera.ru/

NeuroMax is a Russian biotechnology company founded in 2010 with the goal to develop and bring to the Russian market advanced innovative biopharmaceuticals for central and peripheral nervous system disease diagnostics, therapy, prophylaxis and recovery. Since 2011 participant of Technology Platform Medicine of the Future.

To date the Company develops two compounds BNV-222 (diabetic peripheral neuropathy (DPN) and AQU-005 (chronic neuropathic pain).

http://www.neuromax.ru

Infectex is a Russian biotechnology company founded in 2011 with the main goal to develop and market advanced innovative medicines for most dangerous infectious diseases. Infectex is a resident of the Skolkovo Innovation Center since April 2011 and participant of Technology Platform Medicine of the Future.

To date the Company develops two pharmaceuticals for tuberculosis.

http://www.infectex.ru/

Eleventa is a Russian biotechnology company founded in 2012 with the main goal to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases.

Leading drug candidate OС000459 is aimed at the treatment of moderate to severe asthma and other respiratory allergies.

http://www.eleventa.ru/

Osteros Biomedica is a Russian biotechnology company founded in 2012 for the development and commercialization of the medicines for the treatment of cancer induced bone disease.

The first drug to be developed is MBC-11 compound for the treatment of bone cancer.

http://www.osteros.ru/

Photonics is a Russian innovative company founded in 2010, resident of the Skolkovo Innovation Center since June 2011 and participant of Technology Platform Medicine of the Future. Photonics develops and commercializes advanced new-generation medical laser systems for soft and hard tissues surgery.

http://www.laserphotonics.ru/

OncoMax is a Russian biotechnology company founded in 2010 with the goal to develop and commercialize innovative therapies and diagnostics for oncology diseases. OncoMax is a resident of the Skolkovo Innovation Center since April 2011 and participant of Technology Platform Medicine of the Future.

Company’s first product is OM-RCA-01, a humanized monoclonal antibody against Fibroblast Growth Factor Receptor 1 (FGFR1) — novel anticancer target.

http://www.oncomax.ru/

© Maxwell Biotech Group Ltd.

TOP